IgA Nephropathy: A Comprehensive Medical Guide

Overview

IgA nephropathy (also called Berger disease) is a chronic kidney disorder characterized by the deposition of immunoglobulin A (IgA) antibodies in the glomeruli—the tiny filtering units of the kidneys. This immune complex buildup triggers inflammation, which can gradually impair kidney function and, in some people, progress to chronic kidney disease (CKD) or end‑stage renal disease (ESRD).

• Typical age of onset: Adolescents and young adults (15‑30 years), but it can appear at any age.
• Gender: Slight male predominance (≈1.3 : 1).
• Prevalence: Estimated to affect 2–10 % of all kidney biopsies worldwide, making it the most common primary glomerulonephritis in many regions (Mayo Clinic; CDC).
• Geographic variation: Higher incidence in East Asia (Japan, China) and lower rates in Sub‑Saharan Africa.

Symptoms

IgA nephropathy often presents silently, especially in early stages. When symptoms arise, they can be intermittent or persistent.

Common clinical features

• Hematuria (blood in urine): Often visible (gross hematuria) after an upper‑respiratory infection (“synpharyngitic” hematuria). Microscopic hematuria may be the only finding on routine urine tests.
• Proteinuria (protein in urine): Usually <1 g/24 h in early disease, but can rise >3 g/24 h in more advanced cases.
• Edema: Swelling of the ankles, feet, or around the eyes due to fluid retention.
• Hypertension: Elevated blood pressure is present in up to 50 % of patients at diagnosis.
• Decreased kidney function: Elevated serum creatinine or reduced glomerular filtration rate (GFR).

Less common or late‑stage manifestations

• Foamy urine (sign of heavy protein loss)
• Fatigue and generalized weakness
• Loss of appetite or unintended weight loss
• Uremic symptoms (nausea, itching, metallic taste) in advanced CKD

Causes and Risk Factors

IgA nephropathy is considered an immune‑mediated disease. The exact trigger is unknown, but research points to a combination of genetic susceptibility and environmental factors.

Pathophysiology

• Abnormal glycosylation of IgA1 molecules → formation of IgA‑containing immune complexes.
• These complexes deposit in the mesangial region of glomeruli, stimulating inflammation and scarring.

Risk factors

• Family history: First‑degree relatives with IgA nephropathy or other glomerular diseases increase risk (≈10‑15 % have a positive family history).
• Genetic markers: Certain HLA alleles (e.g., HLA‑DRB1*1501) and genome‑wide association loci have been linked to disease susceptibility.
• Respiratory or gastrointestinal infections: Episodes often precede visible hematuria.
• Ethnicity: Higher prevalence in Asians and Caucasians; lower in African descent.
• Male gender: Slightly higher incidence and faster progression.
• Smoking: Associated with faster decline in kidney function.

Diagnosis

Because early IgA nephropathy can be asymptomatic, a high index of suspicion is required when routine urine tests reveal hematuria or proteinuria.

Key diagnostic steps

1. Medical history & physical exam: Focus on recent infections, family history, blood pressure, and edema.
2. Urinalysis: Detects red‑blood‑cell casts (suggests glomerular bleeding) and quantifies protein loss.
3. Blood tests: Serum creatinine, estimated GFR, lipid profile, complement levels (often normal in IgA nephropathy).
4. Imaging: Renal ultrasound to assess kidney size and rule out obstructive causes.
5. Kidney biopsy (gold standard): Light microscopy, immunofluorescence (IgA dominant staining in mesangium), and electron microscopy confirm diagnosis and assess disease severity (MEST‑C scoring).

Prognostic indicators

• Degree of proteinuria (>1 g/24 h correlates with faster progression)
• Decline in eGFR at presentation
• Histologic findings (extent of sclerosis, crescents)

References: National Kidney Foundation, KDIGO Clinical Practice Guideline for Glomerulonephritis (2021); Mayo Clinic.

Treatment Options

Management aims to slow disease progression, control blood pressure, and reduce proteinuria. Treatment is individualized based on risk stratification.

Medications

• Angiotensin‑converting enzyme inhibitors (ACEi) or Angiotensin II receptor blockers (ARBs): First‑line for hypertension and proteinuria reduction. Trials show up to 30 % slower eGFR decline.
• Immunosuppressive therapy:
  • Corticosteroids: Short‑term prednisone (0.5–1 mg/kg/day) can reduce proteinuria in selected high‑risk patients.
  • Mycophenolate mofetil (MMF): May be used as steroid‑sparing agent; evidence remains mixed.
  • Cyclophosphamide: Reserved for rapidly progressive disease with crescent formation.
• Fish‑oil (omega‑3 fatty acids): 2–4 g/day modestly lowers proteinuria in some studies (Cleveland Clinic).
• Statins: Indicated for dyslipidemia to protect cardiovascular health.

Procedures

• Renal replacement therapy (RRT): When eGFR <15 mL/min/1.73 m², dialysis or kidney transplantation becomes necessary.
• Plasmapheresis: Occasionally used in severe, rapidly progressive cases, but not routine.

Lifestyle and supportive measures

• Low‑salt diet (≤2 g sodium per day) to aid blood‑pressure control.
• Protein intake of 0.8–1.0 g/kg body weight (unless on dialysis).
• Regular aerobic exercise (150 min/week) for cardiovascular health.
• Avoidance of NSAIDs and nephrotoxic agents.
• Smoking cessation and moderation of alcohol.

Living with IgA Nephropathy

While the disease can be chronic, many people lead active lives with proper management.

Daily management tips

1. Monitor blood pressure: Aim for <130/80 mm Hg (or as advised by your doctor). Home cuffs are useful.
2. Track urine protein: Periodic urine dipstick or spot urine protein/creatinine ratio helps gauge treatment response.
3. Stay hydrated, but respect fluid limits: In advanced CKD, fluid restriction may be required.
4. Adhere to medication regimen: Use pill organizers or smartphone reminders.
5. Regular follow‑up: At least every 3–6 months for labs; more often if kidney function is rapidly changing.
6. Vaccinations: Annual flu vaccine, hepatitis B, COVID‑19, and pneumococcal vaccines to reduce infection‑related flares.
7. Psychosocial support: Join patient support groups (e.g., National Kidney Foundation) and consider counseling if coping is difficult.

Prevention

Because the exact cause is not fully understood, primary prevention is challenging. However, certain actions can reduce the risk of disease onset or slow progression:

• Maintain optimal blood pressure and control hypertension early.
• Limit exposure to infections—practice good hand hygiene, stay up‑to‑date on vaccinations.
• Avoid chronic use of nephrotoxic drugs (NSAIDs, certain antibiotics).
• Adopt a heart‑healthy diet rich in fruits, vegetables, whole grains, and low in saturated fat.
• Quit smoking and limit alcohol consumption.

Complications

If IgA nephropathy is left untreated or poorly controlled, several serious complications can develop:

• Chronic kidney disease (CKD): Progressive loss of kidney function; 20‑40 % of patients reach ESRD within 20 years.
• End‑stage renal disease (ESRD): Requires dialysis or transplantation.
• Hypertension‑related cardiovascular disease: Heart attack, stroke, and peripheral artery disease are more common in CKD patients.
• Secondary hyperparathyroidism & bone disease: Due to disturbances in calcium‑phosphate metabolism.
• Anemia: Decreased erythropoietin production.
• Infections: Immunosuppressive therapy can increase susceptibility.

When to Seek Emergency Care

© 2026 HealthGuide™ – All information provided is for educational purposes only and does not replace professional medical advice. Consult your nephrologist or primary‑care provider for personalized care.